Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)

非诺贝特治疗腹主动脉瘤 (FAME)

• 批准号: nhmrc : 1020955
• 负责人: A/Pr Reinhold Muller
• 金额: $ 30.39万
• 依托单位: James Cook University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/fenofibrate-management-abdominal-aneurysm-fame/110077
• 关键词: Fenofibrate; management; AbdoMinal; aortic; anEurysm

Approximately 5% of men and 1% of women aged over 60 years develop weakening of the main abdominal artery. Currently the management of artery weakening is focused on surgery with no effective medications available. In this study we will assess whether a drug which limits artery weakening in pre-clinical testing also shows evidence of inhibiting processes important in artery damage in patients. We believe this is a critical next step in the assessment of a promising new treatment.

大约5%的男性和1%的60岁以上的女性会出现腹主动脉的衰弱。目前，动脉变弱的治疗主要集中在手术治疗上，没有有效的药物可用。在这项研究中，我们将评估一种在临床前测试中限制动脉减弱的药物是否也显示出抑制过程的证据，这些过程对患者的动脉损伤至关重要。我们认为，这是评估一种有前景的新疗法的关键下一步。